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Forty endoscopically proven active variceal bleeds were entered in a prospective trial comparing
oesophageal tamponade with SMS 201-995 infusion.
Oesophageal tamponade controlled 19 of 20 bleeds over the first four hours and 14 of 18 bleeds over
48 hours. SMS 201-995 infusion controlled 18 of 20 bleeds over the first four hours and 10 of 20 bleeds
over 48 hours (p 0.15). No significant differences between the groups were seen in time to control of
bleeding, amount of blood transfused or number of patients crossed over to the opposite treatment.
Complications in the oesophageal tamponade group were discomfort due to the tube (17 patients) and
chest infection (10 patients), while in the SMS 201-995 group 7 chest infections and one episode of
hyperglycaemia occurred, with no symptomatic complaints. The patient survived the admission in 15 of
the oesophageal tamponade bleeds and all of the SMS 201-995 bleeds (p =0.047).
An intravenous infusion of SMS 201-995 appears to have comparable efficacy to oesophageal
tamponade in variceal bleeding.
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INTRODUCTION
There is considerable debate as to the best means of safely establishing immediate
control of acute bleeding from oesophageal varices. Oesophageal tamponade has
been shown to be an effective means of control of bleeding1’2’3 but respiratory
complications may arise and patient tolerance is poor. Vasopressin has been the
mainstay of drug treatment over the past thirty years but doubts have been raised as
to its efficacy
4 and serious cardiac side-effects may occur. It has been suggested that
the addition to vasopressin of a vasodilator such as nitroglycerin may reduce the
incidence of side-effects5’6 but the use of a single drug without generalised
cardiovascular side-effects would be simpler. Emergency injection sclerotherapy
has the advantage of initiating definitive treatment rather than only providing
temporary arrest of bleeding7. However considerable expertise is required to
perform sclerotherapy in an actively bleeding patient and prior control of bleeding
may still be needed to permit adequate resuscitation before sclerotherapy can be
undertaken.
We have previously established that a new, long-acting somatostatin analogue,
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SMS 201-995 (Sandostatin, Sandoz Ltd, Basel), causes a 30% reduction in portal
pressure in stable cirrhotic patients8. In two clinical trials, naturally occurring
somatostatin has been shown to be at least as effective as vasopressin in controlling
variceal haemorrhage, with fewer side-effects9’1. However practical problems arise
during its administration due to its instability in solution and its very short half-life.
Furthermore, rebound phenomena have been observed on completion of intrave-
nous infusions of somatostatin1. No rebound phenomena have been observed after
infusion of SMS 201-995, a long-acting octapeptide with a half-life of 45 minutes in
plasma, and its effect on insulin levels is small and short lasting in comparison to its
other effects12. In the present study we have compared the efficacy of SMS 201-995
with the Minnesota modification of the Sengstaken Blakemore tube in early control
of active variceal bleeding.
PATIENTS AND METHODS
Between July 1986 and May 1988, patients admitted to the University Department
of Surgery, Glasgow Royal Infirmary who were demonstrated to have active
bleeding from oesophageal varices at endoscopy were considered for the study.
Portal hypertensive patients with bleeding from other sources were excluded as
were patients who had experienced a myocardial infarction within the preceding six
months, patients with renal failure requiring dialysis and patients with insulin
dependent diabetes mellitus. No patient was on prophylactic beta blockade to
prevent variceal rebleeding.
Following admission to hospital patients were resuscitated with blood and plasma
and fibreoptic endoscopy under sedation (intravenous diazemuls 0 to 30 mg) was
performed within two hours. Prior to endoscopy in patients suspected of having
variceal haemorrhage, the trial was explained and verbal consent obtained from
either the patient or a relative. Having confirmed active bleeding from oesophageal
varices at endoscopy patients were randomised to treatment with SMS 201-995 or
oesophageal tamponade using numbered sealed envelopes. The amount of blood
transfused prior to endoscopy and the time from the start of overt bleeding were
recorded. Patients treated with SMS 201-995 were given an intravenous infusion of
25pg/hr in 120ml 0.9% saline over 48 hours using a syringe pump (Treonic IP4,
Vickers Medical). Patients randomised to oesophageal tamponade had the
Minnesota modification of the Segstaken Blakemore tube (4 lumen) passed
through the mouth or nose by one of three experienced members of medical staff2.
The gastric balloon was inflated with 100ml of saline and 20ml of water-soluble
contrast medium. The oesophageal balloon was inflated to 40mm Hg as indicated
by an anaeroid barometer and the tube taped to the cheek under slight tension. The
tube position was confirmed by chest X-ray immediately after insertion and the
patient was constantly supervised by a trained nurse who aspirated the gastric and
phparyngeal lumina of the tube hourly. Between aspirations the lumina remained
on open drainage. The tube was left in place for 24 hours with both balloons
inflated. At 24 hours the oesophageal balloon was deflated and the tube untaped so
that the gastric balloon lay free in the stomach. This has been our standard method
of emergency treatment for variceal haemorrhage for some years, with ability to
control bleeding in 94% of cases in the past and similar methods are used by otherACUTE VARICEAL HAEMORRHAGE 9
groups1’3. If further bleeding occurred the oesophageal balloon was re-inflated and
the tube taped as before. The tube was removed at 48 hours.
Whole blood and plasma were administered for volume and red cell replace-
ment. Vitamin K, fresh frozen plasma, platelets and/or cryoprecipitate were given
as appropriate if a coagulation defect was demonstrated at the time of the bleed.
Oral lactulose and regular saline rectal washouts were used to prevent or treat
encephalopathy. All patients were closely monitored by hourly blood pressure,
pulse, urine volume and temperature measurements. Patients given SMS 201-995
infusion had a nasogastric tube passed to monitor gastric aspirations hourly. At the
end of the trial period all patients underwent a further fibreoptic endoscopy to
assess control of bleeding and to perform injection sclerotherapy. This study was
approved by the Ethical Committee of the Royal Infirmary, Glasgow.
All patients had clinical examination and the following investigations performed
at 0 and 48 hours: full blood count, coagulation screen, serum urea and electro-
lytes, blood glucose, liver function tests, plasma proteins and arterial blood gases.
An electrocardiogram and chest X-ray were performed at the beginning and the
end of the 48 hour period. Pugh’s modification of Child’s grading
13 was used as an
assessment of liver function and was recorded at 0 and 48 hours for each patient. In
addition, full blood count and blood glucose were repeated 12 hourly and urea and
electrolytes and liver function tests repeated at 24 hours. Two successive creatinine
clearance measurements were also performed during the 48 hour study period.
Clinical examination, chest X-ray and arterial blood gases were repeated at 72
hours and 7 days from admission to the trial. Fluid balance and requirements for
blood and blood products were recorded.
Cessation of bleeding was recorded at the hour when less than 20ml of fresh
blood was aspirated from the stomach provided there was no other evidence of
bleeding. Rebleeding was deemed to have occurred if one or more of the following
criteria were fulfilled:
(a)
(b)
(c)
(d)
overt haemorrhage or aspiration of more than 100ml of fresh blood
passage of fresh blood per rectum
fall in haemoglobin concentration of more than 4g/dl within 48 hours
shock (pulse rate > 100; systolic blood pressure < 100) in the presence of
continuing melaena.
If either treatment failed to control the bleeding or if rebleeding occurred during
the 48 hours of treatment the patient was crossed over immediately to the other
treatment. Control of bleeding was assessed during the first four hours of the trial
period (recorded as initial control), during the first 24 hours and for the whole 48
hour period (complete control). The further progress of the patient during that
admission to hospital was recorded, with particular reference to survival during that
admission and cause of death. Symptomatic side-effects were assessed by enquiry
from the patient. Evidence of chest infection was assessed by clinical examination,
serial chest X-rays and blood gas analysis and was deemed to be present if CXR
showed collapse or consolidation, pO2 deteriorated by more than 15 mm Hg and/or
clinical examination revealed coarse crepitations with the production of purulent
sputum.
Comparisons of the two groups with regard to time to bleeding control from start10 R.F. McKEE ET AL.
of treatment, amount of blood transfused and creatinine clearance values were
carried out using the students t-test. Comparison of the control rate at 24 and 48
hours were performed using Chi-squared tests. Bleeding control rate at 4 hours,
number of rebleeds, number of crossovers and survival were compared using
Fisher’s exact test. p< 0.05 was taken as the level of statistical significance.
RESULTS
The results of this trial are summarised in Figure 1. During the 23 month trial
period, 96 episodes of variceal bleeding occurred in 72 patients. Forty separate
admissions with endoscopically proven active variceal bleeding were included.
Fifty-six bleeds in 41 patients were excluded (Table 1). Thirteen of these excluded
bleeds proved fatal, either due to the bleed itself or its complications.
Forty episodes of variceal haemorrhage in 31 patients were included in the trial.
Twenty bleeds were randomised to oesophageal tamponade (OT) and 20 bleeds to
SMS 201-995 infusion (SMS). These two groups were comparable with regard to
age, sex distribution and aetiology of portal hypertension (Table 2).
Table 1 The reasons for exclusion from the trial of 56 other bleeds thought to be from oesophageal
varices
No active bleeding after admission
Transfer from another hospital with Minnesota tube in place
Danger of exsanguination-tamponade instituted before endoscopy possible
Moribund on admission and could not be resuscitated
Wrong initial diagnosis of Mallory-Weiss tear
No active treatment-terminal disease
Emergency injection sclerotherapy in error
Excluded in error because of age
31
11
5
2
4
Total 56
Table 2 Patient characteristics for the two groups treated with oesophageal tamponade or SMS 201-
995 infusion for active variceal bleeding
Oesophageal SMS 201-995
Tamponade Infusion
Total number 20 20
Sex Ratio (M:F) 16:4 18:2
Age in years- mean (sem) 51.6 (3.3) 49.9 (3.5)
Aetiology
Alcoholic cirrhosis 13 15
Primary biliary cirrhosis 1
Chronic active hepatitis 3 0
Cryptogenic cirrhosis 3
Sclerosing cholangitis 0 1
Drug induced cirrhosis 0
Congenital hepatic fibrosis 0
Pugh’s modification of Child’s grade
A 2
B 4 8
C 15 10ACUTE VARICEAL HAEMORRHAGE 11
The characteristics of the variceal bleeds included in this trial in terms of the
number of first bleeds from varices, the time from its initial manifestation and the
amount of blood given before admission to the trial were similar in the two groups
(Table 3).
Table 3 Characteristics of the bleed for the two groups treated with oesophageal tamponade or SMS
201-995 infusion for active variceal bleeding
Oesophageal SMS 201-995
Tamponade Infusion
Number of first bleeds
Hours from start of overt bleeding- mean (sem)
Number of patients transfused before admission to
trial
Mls of blood transfused per patient transferred
before admission to trial- mean (sem)
6 9
20.5 (4.2) 17.9 (3.6)
11 9
1464 (308) 1867 (291)
Control of Bleeding (Figure 1)
Bleeding was controlled during the first 4 hours after admission to the trial in 19 of
20 bleeds treated with oesophageal tamponade and 18 of 20 bleeds treated with
SMS 201-995 infusion. In the one bleed in which haemorrhage was not controlled
by tamponade, crossover to SMS 201-995 infusion was undertaken at two hours but
this failed to control the bleeding. Bleeding was controlled by injection sclerother-
apy but the patient died of hepatorenal failure at 40 hours from admission to the
trial. This patient had a very poor prognosis on admission, having Grade III
encephalopathy and a prothrombin time of 40 seconds3. In the two instances where
haemorrhage was not controlled by SMS 201-995 infusion during the first 4 hours,
crossover to oesophageal tamponade resulted in cessation of the bleeding.
In the oesophageal tamponade group 15 bleeds stopped immediately treatment
was started, while in four other patients small amounts of fresh blood (< 100ml/hr,
stopped by 4 hours) were aspirated for several hours before bleeding stopped
completely (Figure 1). In the SMS 201-995 group 11 bleeds stopped completely
within the first hour while seven bleeds took longer to settle. This difference in time
to control bleeding is not statistically significant (p 0.24).
Over the 48 hour trial period, two patients in the oesophageal tamponade group
died, the patient mentioned above whose bleeding was uncontrolled by tamponade
and SMS 201-995 infusion, and one patient who died at 4.5 hours from admission
due to severe metabolic upset secondary to preexisting hepatorenal failure. At 24
hours from admission, 16 of 19 patients alive in the OT group had no further
bleeding. In two patients rebleeding occurred during the first 24 hours when the
oesophageal balloon should have been inflated, but in one instance this had been
accidentally deflated and in the other the oesophageal balloon had burst. In 14 of
the remaining 18 bleeds in the OT group there was no further bleeding over 48
hours. Two other rebleeds occurred during the second 24 hours when the oesopha-
geal balloon was deflated. In the OT group all four of these rebleeds were easily
controlled by either re-inflation of the oesophageal balloon or the insertion of a12 R.F. McKEE ET AL.
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Figure 1 The clinical course in 40 active variceal bleeds entered in this study of oesophageal
tamponade compared to SMS 201-995 infusion, with particular regard to control of bleeding.
new Minnesota tube in the case where the balloon had burst. Therefore no patient
required crossover to SMS 201-995 infusion because of rebleeding.
In the SMS group 14 of 20 patients had no further bleeding at 24 hours (p< 0.5
cf. OT group) and 10 patients had had no bleeding at 48 hours. In 8 instances there
was evidence of rebleeding but in four cases this settled without treatment. Four
rebleeds required crossover to oesophageal tamponade and the bleeding was
controlled by this in each case. The difference in 48 hour bleeding control rate is
not statistically significant (p 0.15).
The 20 bleeds in the oesophageal tamponade group required a mean of 1680 mls
(sem 295 mls) of blood transfusion over the 7 day trial period while the 20 bleeds in
the SMS 201-995 group required a mean of 1710 mls (sem 252 mls) (p =0.4).
Complications
In 22 of the 26 bleeds treated at some time by oesophageal tamponade, the patient
complained of discomfort caused by the Minnesota tube. All of the other 4 patients
had hepatic encephalopathy. In the 21 bleeds treated with SMS 201-995 infusion
there were no symptomatic side-effects.
No patient in the OT group required insulin therapy to control hyperglycaemia.
In the SMS group, one patient who was a no insulin dependent diabetic required an
intravenous infusion of soluble insulin of 1-2 units/hour to maintain his plasma
glucose below 15 mmol/1 but this easily controlled the plasma glucose level which
remained stable when the SMS 201-995 infusion was stopped. No other patientACUTE VARICEAL HAEMORRHAGE 13
required insulin infusion despite the fact that two other bleeds in the SMS group
occurred in maturity onset diabetics.
In 15 of the bleeds treated with oesophageal tamponade two consecutive
creatinine clearance measurements were made. The mean of the mean creatinine
clearance values for each individual was 106ml/min (sem 10). The mean creatinine
clearance rate in 16 patients treated with SMS 201-995 infusion was 84ml/min (sem
9). The values for the two groups are not significantly different (p 0.1).
Chest infection developed after 17 of the 39 bleeds evaluable. The patient who
died at 4.5 hours has not been included. The details of treatment and the incidence
of uncontrolled or recurrent bleeding in these cases are shown in Table 4. There is a
significant association between chest infections and rebleeding (p=0.05) but no
association between chest infection and treatment with oesophageal tamponade
(p 0.25).
Table4 Incidence of chest infections in comparison with type of treatment and occurrence of
rebleeding
Total number
Chest ofpatients
infection in group
SMS 201-995 infusion group
Oesopageal tamponade group
SMS 201-995 infusion alone
SMS 201-995 and tamponade
Oesophageal tamponade alone
Uncontrolled bleed or rebleed
No further bleed
7 20
10 19
4 14
4 7
9 18
10 15
7 24
Survival
None of the 20 bleeds in the SMS 201-995 group proved fatal, in comparison with 5
deaths from the 20 bleeds in the oesophageal tamponade group (p =0.47). Three
patients died of hepatorenal failure at 4.5 hours, 40 hours and 9 days from entry to
the study. One patient died at 9 days from entry to the study when he suddenly had
a further haematemesis, aspirated and could not be resuscitated. The fifth patient
died at four days from study entry after an oesophageal perforation had occurred at
rigid oesophagoscopy. Rigid oesophagoscopy and sclerotherapy had been per-
formed on two occasions within 48 hours in order to try to control the patient’s
variceal bleeding which had recurred immediately after fibreoptic endoscopy and
sclerotherapy. This patient was not felt to be fit for any other intervention. All five
patients who died were modified Child’s grade C.
DISCUSSION
In this trial a 25/g/hr intravenous infusion of SMS 201-995 controlled bleeding14 R.F. McKEE ET AL.
during the first four hours of treatment in 18 of 20 active bleeds from oesophageal
varices. However the control rate had fallen to 70% by 24 hours and 50% by 48
hours. Oesophageal tamponade was able to control more bleeds without crossover,
although this difference did not reach statistical significance in the relatively small
number of bleeds studied.
Two previous controlled clinical trials have compared the naturally occurring
tetradecapeptide somatostatin with vasopressin in variceal bleeding. The results of
the present study are similar to the results of Kravetz et al. 9, where 16 of 30
episodes of variceal haemorrhage were controlled by somatostatin for 48 hours,
although inferior to the results of the Liverpool group1, who found that variceal
haemorrhage was controlled for 24 hours by somatostatin infusion in all 10 patients
in whom it was employed. Since we have shown a deterioration in control of
bleeding with time, the difference in results may be due to the longer trial period in
both the study by Kravetz and colleagues
9 and the present study. In the study of
Jenkins and co-workers1, somatostatin was only given to ten patients and the small
numbers in all of the studies9’1 may help account for the apparent differences. In
more recent placebo controlled studies, one multicentre trialTM failed to show
significant benefit in that in the 30 hour study period 65% of the patients given
somatostatin stopped bleeding as opposed to 83% of those given placebo. Despite
the somewhat surprising "success" of placebo, transfusion requirements and
mortality rates were similar in the two groups. In a trial from the Royal Free
Hospital, London, somatostatin proved significantly more effective than placebo in
controlling bleeding (64% versus 41%) and when bleeding recurred it did so earlier
in the placebo group15. Somatostatin significantly reduced blood and plasma
transfusion requirement and halved the need for balloon tamponade. Although it
was concluded that somatostatin was safe and more effective at controlling bleeding
than placebo, 30 day mortality was not affected.
In our situation we felt that a 48 hour trial comparing SMS 201-995 infusion with
placebo would be difficult to justify and we have therefore compared SMS 201-995
infusion with the previous best means of immediate treatment in our department2.
The fact that SMS 201-995 infusion was carried out for 48 hours is balanced by the
fact that the Minnesota tube was left in place for this period so that tamponade
could be continued if necessary. Although emergency sclerotherapy may be the
ideal means of treatment the necessary expertise and facilities are not always
immediately available and some means of emergency treatment is essential.
Previous controlled trials in variceal bleeding have achieved variable control rates
with placebo- ranging from 25% at 24 hours6, through 37% at 8 hours7 to 45% at
24 hoursTM. Strict comparison of trials is difficult because of differences in the
severity of bleeds included, in the accuracy of diagnosis, in the means of conserva-
tive treatment, in the length of the trial period and in the methods used to assess
control of haemorrhage. Furthermore, although the number of bleeding episodes
in the current trial is similar to other recent controlled trials9’1, it must not be
forgotten that the number of variceal bleeds required in a controlled trial to achieve
even 50% power, assuming a substantial difference in bleeding control rates, is
more than two hundred.
Although oesophageal tamponade has proved an effective means of controlling
variceal bleeding in the past, it has several potential serious side-effects and a
comparison of the incidence of side-effects in the two groups in this trial is ofACUTE VARICEAL HAEMORRHAGE 15
considerable importance. In the present study discomfort from the Minnesota tube
was a major complaint in 22 of the 26 patients treated with tamponade and this
dislike of tamponade contrasted markedly with the lack of symptomatic side-effects
in the patients treated only with SMS 201-995 infusion. Despite the fact that
somatostatin plays a role in blocking both insulin and glucagon release at physiolo-
gical levels (19) only one patient developed an abnormality of glucose homeostasis
during SMS 210-995 infusion and this was controlled easily. Vora et al.2 have
reported a reduction in renal function due to SMS 201-995. In patients with portal
hypertension and actively bleeding varices many factors can influence a relatively
simple measurement of renal function such as creatinine clearance but there was no
significant difference in creatinine clearance rates in the two groups of patients in
the present study. Furthermore no patient posed clinical problems with renal
function while receiving an infusion of SMS 210-995.
Previous reports regarding the use of oesophageal tamponade have emphasised
the risk of chest complications with this treatment. Novis et al. 21 noted 8 chest
infections in 40 bleeds while Conn et al.
22 reported 8 cases of aspiration and one
case of respiratory obstruction in 40 bleeds. In a complex clinical situation the exact
cause of such chest infections is difficult to assess. However, if this incidence of
chest infection was associated with tamponade alone, a reduction in this complica-
tion would have been expected in the group of patients treated with SMS 201-995
infusion only. This study has shown (Table 4) that chest infection was associated
significantly with rebleeding or continued bleeding but not with tamponade. The
finding that oesophageal tamponade was not associated with an increased risk of
chest infection is initially surprising in view of the previous reports of this
complication1’21’22’23. However in these severely ill patients there are a number of
factors such as vomiting, sedation and endoscopy which might increase the risk of
chest infection. It is difficult to determine which factor is of greatest importance.
In comparing treatments for variceal haemorrhage it is also worth considering
that the administration of a drug infusion requires less expertise on the part of the
medical and nursing staff than oesophageal tamponade. This may be a significant
advantage in hospitals where relatively few patients with variceal bleeding are seen
and an SMS 201-995 infusion may facilitate the patient’s safe transfer to a
specialised centre. The reduction in bleeding control rate with time emphasises that
immediate treatment of variceal haemorrhage to control bleeding should be
followed rapidly by definitive treatment to prevent rebleeding such as injection
sclerotherapy. It is clear in retrospect that this definitive treatment should be
performed earlier than 48 hours.
In this trial five patients were excluded because they had been judged to be
exsanguinating by the staff of the Accident and Emergency Department and had
been treated immediately by oesophageal tamponade, the standard hospital treat-
ment. SMS 201-995 was not available to the A&E staff at that time. This may have
excluded some of the severe bleeds from this trial but our strict entry criteria of
active variceal bleeding at endoscopy probably also excluded a number of mild
variceal bleeds. It may be that oesophageal tamponade will be necessary for the
most severe bleeds, although its use was progmatic in the cases described above.
The main aim of this trial was to assess theeffect of SMS 201-995 on bleeding
from oesophageal varices and the finding of a higher survival rate in the SMS 201-
995 group was unexpected. Stratification to account for liver function was not16 R.F. McKEE ET AL.
practical in a small trial and despite randomisation there was a greater number of
patients with poor liver function in the tamponade group. Therefore the difference
in survival may be artefactual due to the small numbers.
In conclusion, infusion of SMS 201-995 would appear to have certain advantages
over oesophageal tamponade for the immediate control of bleeding oesophageal
varices, with any reduction in bleeding control being offset by its better tolerability.
However, control deteriorates with time and it is possible that its future role may be
in the temporary control of bleeding while the patient is resuscitated before acute
injection sclerotherapy is undertaken.
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